Genetics, Epigenetics, and Genomics of Systemic Sclerosis

Rheumatic Disease Clinics of North America

Volumn 41, Issue 3, 2015, Pages 345-366

  Salazar, Gloria ^a   Mayes, Maureen D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Epigenetics; Gene expression; Genetics; MicroRNA; MiRNA; Scleroderma; Splicing; Systemic sclerosis

Indexed keywords

HLA ANTIGEN; LONG UNTRANSLATED RNA; MICRORNA; SPACER DNA;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; EPIGENETICS; ETHNIC DIFFERENCE; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE INTERACTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEREDITY; HERITABILITY; HUMAN; INNATE IMMUNITY; INTRON; MAJOR HISTOCOMPATIBILITY COMPLEX; METAGENOMICS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; REVIEW; RNA SPLICING; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS; X CHROMOSOME; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMAN GENOME; IMMUNOLOGY; MUTATION; PATHOLOGY; PHYSIOLOGY;

AUTOIMMUNE DISEASES; EPIGENOMICS; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HLA ANTIGENS; HUMANS; MUTATION; QUANTITATIVE TRAIT LOCI; SCLERODERMA, SYSTEMIC;

EID: 84937976707     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2015.04.001     Document Type: Review

References (103)

1. Mayes M.D., Bossini-Castillo L., Gorlova O., et al. Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am J Hum Genet 2014, 94(1):47-61.
2. Agarwal S.K. The genetics of systemic sclerosis. Discov Med 2010, 10(51):134-143.
3. Granel B., Bernard F., Chevillard C. Genetic susceptibility to systemic sclerosis from clinical aspect to genetic factor analyses. Eur J Intern Med 2009, 20(3):242-252.
4. Allanore Y., Dieude P., Boileau C. Genetic background of systemic sclerosis: autoimmune genes take centre stage. Rheumatology (Oxford) 2010, 49(2):203-210.
5. Zhou X., Tan F.K., Wang N., et al. Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum 2003, 48(9):2585-2592.
6. Hudson M., Rojas-Villarraga A., Coral-Alvarado P., et al. Polyautoimmunity and familial autoimmunity in systemic sclerosis. J Autoimmun 2008, 31(2):156-159.
7. Martin J., Fonseca C. The genetics of scleroderma. Curr Rheumatol Rep 2011, 13(1):13-20.
8. Mayes M.D. The genetics of scleroderma: looking into the postgenomic era. Curr Opin Rheumatol 2012, 24(6):677-684.
9. Broen J.C., Coenen M.J., Radstake T.R. Genetics of systemic sclerosis: an update. Curr Rheumatol Rep 2012, 14(1):11-21.
10. Broen J.C., Radstake T.R., Rossato M. The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nat Rev Rheumatol 2014, 10(11):671-681.
11. Romano E., Manetti M., Guiducci S., et al. The genetics of systemic sclerosis: an update. Clin Exp Rheumatol 2011, 29(2 Suppl 65):S75-S86.
12. Assassi S., Radstake T.R., Mayes M.D., et al. Genetics of scleroderma: implications for personalized medicine?. BMC Med 2013, 11:9.
13. Radstake T.R., Gorlova O., Rueda B., et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010, 42(5):426-429.
14. Allanore Y., Saad M., Dieude P., et al. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet 2011, 7(7):e1002091.
15. Martin J.E., Bossini-Castillo L., Martin J. Unraveling the genetic component of systemic sclerosis. Hum Genet 2012, 131(7):1023-1037.
16. Martin J.E., Assassi S., Diaz-Gallo L.M., et al. A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Hum Mol Genet 2013, 22(19):4021-4029.
17. Agarwal S.K., Tan F.K., Arnett F.C. Genetics and genomic studies in scleroderma (systemic sclerosis). Rheum Dis Clin North Am 2008, 34(1):17-40.
18. Tan F.K., Arnett F.C. Genetic factors in the etiology of systemic sclerosis and Raynaud phenomenon. Curr Opin Rheumatol 2000, 12(6):511-519.
19. Tan F.K. Systemic sclerosis: the susceptible host (genetics and environment). Rheum Dis Clin North Am 2003, 29(2):211-237.
20. Arnett F.C., Gourh P., Shete S., et al. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis 2010, 69(5):822-827.
21. Gorlova O., Martin J.E., Rueda B., et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet 2011, 7(7):e1002178.
22. Reich K., Huffmeier U., Konig I.R., et al. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis Rheum 2007, 56(6):2056-2064.
23. Wu M., Assassi S. The role of type 1 interferon in systemic sclerosis. Front Immunol 2013, 4:266.
24. Carmona F.D., Cenit M.C., Diaz-Gallo L.M., et al. New insight on the Xq28 association with systemic sclerosis. Ann Rheum Dis 2013, 72(12):2032-2038.
25. D'Amico F., Skarmoutsou E., Marchini M., et al. Genetic polymorphisms of FOXP3 in Italian patients with systemic sclerosis. Immunol Lett 2013, 152(2):109-113.
26. Westra H.J., Franke L. From genome to function by studying eQTLs. Biochim Biophys Acta 2014, 1842(10):1896-1902.
27. Wittkopp P.J. Genomic sources of regulatory variation in cis and in trans. Cell Mol Life Sci 2005, 62(16):1779-1783.
28. Bryois J., Buil A., Evans D.M., et al. Cis and trans effects of human genomic variants on gene expression. PLoS Genet 2014, 10(7):e1004461.
29. Hindorff L.A., Sethupathy P., Junkins H.A., et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 2009, 106(23):9362-9367.
30. De C.L., Baralle M., Buratti E. Exon and intron definition in pre-mRNA splicing. Wiley Interdiscip Rev RNA 2013, 4(1):49-60.
31. Lewandowska M.A. The missing puzzle piece: splicing mutations. Int J Clin Exp Pathol 2013, 6(12):2675-2682.
32. Seth P., Walker L.C., Yeowell H.N. Identification of exonic cis-elements regulating the alternative splicing of scleroderma-associated lysyl hydroxylase 2 mRNA. J Invest Dermatol 2011, 131(2):537-539.
33. Hulse A.M., Cai J.J. Genetic variants contribute to gene expression variability in humans. Genetics 2013, 193(1):95-108.
34. Westra H.J., Peters M.J., Esko T., et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet 2013, 45(10):1238-1243.
35. van R.E. The art of microRNA research. Circ Res 2011, 108(2):219-234.
36. Jiang X., Tsitsiou E., Herrick S.E., et al. MicroRNAs and the regulation of fibrosis. FEBS J 2010, 277(9):2015-2021.
37. He Y., Huang C., Lin X., et al. MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases. Biochimie 2013, 95(7):1355-1359.
38. Vettori S., Gay S., Distler O. Role of MicroRNAs in fibrosis. Open Rheumatol J 2012, 6:130-139.
39. Sethupathy P., Megraw M., Hatzigeorgiou A.G. A guide through present computational approaches for the identification of mammalian microRNA targets. Nat Methods 2006, 3(11):881-886.
40. Imamura K., Akimitsu N. Long non-coding RNAs involved in immune responses. Front Immunol 2014, 5:573.
41. Dieude P., Guedj M., Wipff J., et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009, 60(8):2472-2479.
42. Dieude P., Wipff J., Guedj M., et al. BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. Arthritis Rheum 2009, 60(11):3447-3454.
43. Assassi S., Mayes M.D. What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis?. Curr Opin Rheumatol 2013, 25(6):686-691.
44. Sargent J.L., Whitfield M.L. Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling. Expert Rev Clin Immunol 2011, 7(4):463-473.
45. Whitfield M.L., Finlay D.R., Murray J.I., et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003, 100(21):12319-12324.
46. Gardner H., Shearstone J.R., Bandaru R., et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006, 54(6):1961-1973.
47. Assassi S., Wu M., Tan F.K., et al. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum 2013, 65(11):2917-2927.
48. Sharif R., Mayes M.D., Tan F.K., et al. IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann Rheum Dis 2012, 71(7):1197-1202.
49. Dieude P., Guedj M., Wipff J., et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 2009, 60(1):225-233.
50. Dieude P., Dawidowicz K., Guedj M., et al. Phenotype-haplotype correlation of IRF5 in systemic sclerosis: role of 2 haplotypes in disease severity. J Rheumatol 2010, 37(5):987-992.
51. Carmona F.D., Martin J.E., Beretta L., et al. The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis. PLoS One 2013, 8(1):e54419.
52. Ito I., Kawaguchi Y., Kawasaki A., et al. Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum 2009, 60(6):1845-1850.
53. Carmona F.D., Gutala R., Simeon C.P., et al. Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis. Ann Rheum Dis 2012, 71(1):114-119.
54. Dieude P., Guedj M., Wipff J., et al. NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis. Ann Rheum Dis 2011, 70(4):668-674.
55. Rueda B., Gourh P., Broen J., et al. BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. Ann Rheum Dis 2010, 69(4):700-705.
56. Gourh P., Agarwal S.K., Martin E., et al. Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. J Autoimmun 2010, 34(2):155-162.
57. Ito I., Kawaguchi Y., Kawasaki A., et al. Association of the FAM167A-BLK region with systemic sclerosis. Arthritis Rheum 2010, 62(3):890-895.
58. Coustet B., Dieude P., Guedj M., et al. C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large French cohort and meta-analysis. Arthritis Rheum 2011, 63(7):2091-2096.
59. Dieude P., Bouaziz M., Guedj M., et al. Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1 196Phe/532Ser haplotype. Arthritis Rheum 2011, 63(12):3979-3987.
60. Gourh P., Agarwal S.K., Divecha D., et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum 2009, 60(12):3794-3806.
61. Rueda B., Broen J., Simeon C., et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009, 18(11):2071-2077.
62. Tsuchiya N., Kawasaki A., Hasegawa M., et al. Association of STAT4 polymorphism with systemic sclerosis in a Japanese population. Ann Rheum Dis 2009, 68(8):1375-1376.
63. Dieude P., Boileau C., Guedj M., et al. Independent replication establishes the CD247 gene as a genetic systemic sclerosis susceptibility factor. Ann Rheum Dis 2011, 70(9):1695-1696.
64. Dieude P., Guedj M., Wipff J., et al. Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann Rheum Dis 2010, 69(11):1958-1964.
65. Martin J.E., Broen J.C., Carmona F.D., et al. Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Hum Mol Genet 2012, 21(12):2825-2835.
66. Koumakis E., Giraud M., Dieude P., et al. Brief report: candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity. Arthritis Rheum 2012, 64(8):2746-2752.
67. Gourh P., Tan F.K., Assassi S., et al. Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum 2006, 54(12):3945-3953.
68. Dieude P., Guedj M., Wipff J., et al. The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis. Arthritis Rheum 2008, 58(7):2183-2188.
69. Diaz-Gallo L.M., Gourh P., Broen J., et al. Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Ann Rheum Dis 2011, 70(3):454-462.
70. Gourh P., Arnett F.C., Tan F.K., et al. Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. Ann Rheum Dis 2010, 69(3):550-555.
71. Bossini-Castillo L., Broen J.C., Simeon C.P., et al. A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Ann Rheum Dis 2011, 70(4):638-641.
72. Coustet B., Bouaziz M., Dieude P., et al. Independent replication and meta analysis of association studies establish TNFSF4 as a susceptibility gene preferentially associated with the subset of anticentromere-positive patients with systemic sclerosis. J Rheumatol 2012, 39(5):997-1003.
73. Dieude P., Guedj M., Truchetet M.E., et al. Association of the CD226 Ser (307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. Arthritis Rheum 2011, 63(4):1097-1105.
74. Bossini-Castillo L., Simeon C.P., Beretta L., et al. A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. Arthritis Res Ther 2012, 14(2):R85.
75. Mattuzzi S., Barbi S., Carletto A., et al. Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. J Rheumatol 2007, 34(5):997-1004.
76. Martin J.E., Carmona F.D., Broen J.C., et al. The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis. Genes Immun 2012, 13(2):191-196.
77. Cenit M.C., Simeon C.P., Vonk M.C., et al. Influence of the IL6 gene in susceptibility to systemic sclerosis. J Rheumatol 2012, 39(12):2294-2302.
78. Crilly A., Hamilton J., Clark C.J., et al. Analysis of the 5' flanking region of the interleukin 10 gene in patients with systemic sclerosis. Rheumatology (Oxford) 2003, 42(11):1295-1298.
79. Hudson L.L., Rocca K.M., Kuwana M., et al. Interleukin-10 genotypes are associated with systemic sclerosis and influence disease-associated autoimmune responses. Genes Immun 2005, 6(3):274-278.
80. Bossini-Castillo L., Martin J.E., Broen J., et al. A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet 2012, 21(4):926-933.
81. Granel B., Chevillard C., Allanore Y., et al. Evaluation of interleukin 13 polymorphisms in systemic sclerosis. Immunogenetics 2006, 58(8):693-699.
82. Diaz-Gallo L.M., Simeon C.P., Broen J.C., et al. Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Ann Rheum Dis 2013, 72(7):1233-1238.
83. Agarwal S.K., Gourh P., Shete S., et al. Association of interleukin 23 receptor polymorphisms with anti-topoisomerase-I positivity and pulmonary hypertension in systemic sclerosis. J Rheumatol 2009, 36(12):2715-2723.
84. Karrer S., Bosserhoff A.K., Weiderer P., et al. The -2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol 2005, 124(1):92-98.
85. Tan F.K., Wang N., Kuwana M., et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 2001, 44(4):893-901.
86. Wipff J., Giraud M., Sibilia J., et al. Polymorphic markers of the fibrillin-1 gene and systemic sclerosis in European Caucasian patients. J Rheumatol 2008, 35(4):643-649.
87. Fonseca C., Lindahl G.E., Ponticos M., et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007, 357(12):1210-1220.
88. Zhou X., Tan F.K., Reveille J.D., et al. Association of novel polymorphisms with the expression of SPARC in normal fibroblasts and with susceptibility to scleroderma. Arthritis Rheum 2002, 46(11):2990-2999.
89. Makino K., Jinnin M., Hirano A., et al. The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma. J Immunol 2013, 190(8):3905-3915.
90. Zhu H., Li Y., Qu S., et al. MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma. J Clin Immunol 2012, 32(3):514-522.
91. Maurer B., Stanczyk J., Jungel A., et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 2010, 62(6):1733-1743.
92. Takemoto R., Jinnin M., Wang Z., et al. Hair miR-29a levels are decreased in patients with scleroderma. Exp Dermatol 2013, 22(12):832-833.
93. Tanaka S., Suto A., Ikeda K., et al. Alteration of circulating miRNAs in SSc: miR-30b regulates the expression of PDGF receptor beta. Rheumatology (Oxford) 2013, 52(11):1963-1972.
94. Li H., Yang R., Fan X., et al. MicroRNA array analysis of microRNAs related to systemic scleroderma. Rheumatol Int 2012, 32(2):307-313.
95. Nakashima T., Jinnin M., Yamane K., et al. Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 2012, 188(8):3573-3583.
96. Honda N., Jinnin M., Kira-Etoh T., et al. miR-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin β3. Am J Pathol 2013, 182(1):206-216.
97. Honda N., Jinnin M., Kajihara I., et al. TGF-β-mediated downregulation of microRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts. J Immunol 2012, 188(7):3323-3331.
98. Wang Z., Jinnin M., Kudo H., et al. Detection of hair-microRNAs as the novel potent biomarker: evaluation of the usefulness for the diagnosis of scleroderma. J Dermatol Sci 2013, 72(2):134-141.
99. Makino K., Jinnin M., Aoi J., et al. Discoidin domain receptor 2-microRNA 196a-mediated negative feedback against excess type I collagen expression is impaired in scleroderma dermal fibroblasts. J Invest Dermatol 2013, 133(1):110-119.
100. Kajihara I., Jinnin M., Yamane K., et al. Increased accumulation of extracellular thrombospondin-2 due to low degradation activity stimulates type I collagen expression in scleroderma fibroblasts. Am J Pathol 2012, 180(2):703-714.
101. Zhu H., Luo H., Li Y., et al. MicroRNA-21 in scleroderma fibrosis and its function in TGF-β-regulated fibrosis-related genes expression. J Clin Immunol 2013, 33(6):1100-1109.
102. Sing T., Jinnin M., Yamane K., et al. microRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma. Rheumatology (Oxford) 2012, 51(9):1550-1556.
103. Makino K., Jinnin M., Kajihara I., et al. Circulating miR-142-3p levels in patients with systemic sclerosis. Clin Exp Dermatol 2012, 37(1):34-39.